McDermott Will & Schulte, a global law firm

McDermott Will & Emery has advised Elkedonia, an innovative company specializing in the development of neuroplastogens for the treatment of depressive and neuropsychiatric disorders, in connection with its first fundraising round.

Elkedonia, a start-up launched by Argobio, has successfully closed an initial financing round co-led by Kurma Partners, WE Life Sciences, and the French Tech Seed fund—managed on behalf of the French government by Bpifrance as part of the France 2030 initiative—with participation from Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est, and Sambrinvest.

This €11.25 million transaction aims to support the development of potentially groundbreaking and fast-acting treatments for treatment-resistant depression and other neuropsychiatric disorders, offering an alternative to existing drugs such as ketamine.

The McDermott team advising on the transaction included, Anthony Paronneau, Partner; Natacha Vasak, Associate; Pauline Orliange, Associate.

Leading organizations turn to global law firm McDermott Will & Emery for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. With more than 1,400 lawyers across 20+ offices worldwide, we leverage data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.